Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3145095

Next Previous
Drug Profile

GSK 3145095

Alternative Names: GSK3145095

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics
  • Mechanism of Action RIPK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 Oct 2019 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (GlaxoSmithKline pipeline, October 2019)
  • 30 Oct 2019 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Second-line therapy or greater) in USA (PO) (GlaxoSmithKline pipeline, October 2019)
  • 12 Sep 2019 GlaxoSmithKline terminates a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent, Monotherapy, Combination therapy) in USA following an internal review of the company's current research and development portfolio (PO, Tablet, Capsule) (NCT03681951)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top